Get started
Alkermes plcAlkermes plcAlkermes plc

Alkermes plc

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Options

ALKS chart


Full chart

ALKS upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪4.61 B‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
12.82
Basic EPS (TTM)
2.23 USD
Net income (FY)
‪367.07 M‬ USD
Revenue (FY)
‪1.56 B‬ USD
Shares float
‪160.59 M‬
Beta (1Y)
0.78

Employees


Employees (FY)
‪1.8 K‬
Change (1Y)
−300 −14.29%
Revenue / Employee (1Y)
‪865.35 K‬ USD
Net income / Employee (1Y)
‪206.74 K‬ USD

About Alkermes plc


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Richard F. Pops
Website
alkermes.com
Headquarters
Dublin
Founded
2011
ISIN
IE00B56GVS15
FIGI
BBG000C9F2F9
Alkermes Plc is a global biopharmaceutical company, which engages in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas such as alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. Its proprietary products include ARISTADA, ARISTADA INITIO, LYBALVI, and VIVITROL. The company was founded in 1987 and is headquartered in Dublin, Ireland.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

ALKS news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Check out other big names from the same industry as ALKS.

Frequently Asked Questions


The current price of ALKS is 27.00 USD — it has decreased by −2.65% in the past 24 hours. Watch Alkermes plc stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Alkermes plc stocks are traded under the ticker ALKS.
ALKS stock has fallen by −1.52% compared to the previous week, the month change is a −19.79% fall, over the last year Alkermes plc has showed a 12.78% increase.
We've gathered analysts' opinions on Alkermes plc future price: according to them, ALKS price has a max estimate of 52.00 USD and a min estimate of 30.00 USD. Watch ALKS chart and read a more detailed Alkermes plc stock forecast: see what analysts think of Alkermes plc and suggest that you do with its stocks.
ALKS reached its all-time high on Mar 1, 2000 with the price of 98.50 USD, and its all-time low was 0.94 USD and was reached on Dec 19, 1994. View more price dynamics on ALKS chart.
See other stocks reaching their highest and lowest prices.
ALKS stock is 2.00% volatile and has beta coefficient of 0.78. Track Alkermes plc stock price on the chart and check out the list of the most volatile stocks — is Alkermes plc there?
Today Alkermes plc has the market capitalization of ‪4.48 B‬, it has decreased by −3.02% over the last week.
Yes, you can track Alkermes plc financials in yearly and quarterly reports right on TradingView.
Alkermes plc is going to release the next earnings report on Apr 23, 2025. Keep track of upcoming events with our Earnings Calendar.
ALKS earnings for the last quarter are 1.05 USD per share, whereas the estimation was 0.76 USD resulting in a 38.26% surprise. The estimated earnings for the next quarter are 0.25 USD per share. See more details about Alkermes plc earnings.
Alkermes plc revenue for the last quarter amounts to ‪429.99 M‬ USD, despite the estimated figure of ‪379.39 M‬ USD. In the next quarter, revenue is expected to reach ‪302.97 M‬ USD.
ALKS net income for the last quarter is ‪146.50 M‬ USD, while the quarter before that showed ‪92.38 M‬ USD of net income which accounts for 58.59% change. Track more Alkermes plc financial stats to get the full picture.
No, ALKS doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Apr 17, 2025, the company has ‪1.8 K‬ employees. See our rating of the largest employees — is Alkermes plc on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Alkermes plc EBITDA is ‪449.17 M‬ USD, and current EBITDA margin is 28.84%. See more stats in Alkermes plc financial statements.
Like other stocks, ALKS shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Alkermes plc stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Alkermes plc technincal analysis shows the strong sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Alkermes plc stock shows the sell signal. See more of Alkermes plc technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.